Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: Secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels

International Clinical Psychopharmacology

Volumn 29, Issue 2, 2014, Pages 93-105

  Montgomery, Stuart A ^a   Altamura, A Carlo ^b   Katila, Heikki ^c   Datto, Catherine ^d   Szamosi, Johan ^e   Eriksson, Hans ^e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d ASTRAZENECA   (United Kingdom)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

Anxiety; Elderly; Extended Release Quetiapine Fumarate; Major Depressive Disorder; Pain; Sleep Disturbance

Indexed keywords

AGED; ANTIPSYCHOTIC AGENTS; ANXIETY; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PAIN; PSYCHIATRIC STATUS RATING SCALES; SLEEP DISORDERS;

EID: 84895072385     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000007     Document Type: Article

References (59)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. Fourth edition. Washington, DC: American Psychiatric Association.
2. American Psychiatric Association (2000). D iagnostic and Statistical Manual of Mental Disorders. Fourth edition text revision. Washington, DC: American Psychiatric Association.
3. Aó uera-Ortiz L, Failde I, Mico JA, Cervilla J, Ló pez-Ibor JJ (2011). Pain as a symptom of depression: Prevalence and clinical correlates in patients attending psychiatric clinics. J Affect Disord 130:106-112.
4. Arnold L M, Meyers AL, Sunderajan P, Montano CB, Kass E, Trivedi M, et al. (2008). The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Ann Clin Psychiatry 20:187-193.
5. AstraZeneca Pharmaceuticals (Ireland) Ltd (2013). Seroquel XR - summary of product characteristics for Ireland, revised 2013. Available at: Http://www.medicines.ie/medicine/13032/SPC/Seroquel + XR+ 50mg%2c + 150 mg%2c+200mg% 2c+300mg%2c+400mg+prolonged-release+tablets/. [Accessed 3 July 2013].
6. AstraZeneca Pharmaceuticals LP (2013). Seroquel XR (quetiapine fumarate) extended release tablets prescribing information. Available at: Http://www1.astraze necaus. com/pi/seroquelxr.pdf [Accessed 3 July 2013].
7. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, et al. (2010). Extended-release quetiapine fumarate (quetiapine XR): A once-daily monotherapy ef fective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 13:305-320.
8. Bauer M, Pretorius HW, Constant EL, Earley WR, Szam osi J, Brecher M (2009). Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70:540-549.
9. Bortnick B, El-Khalili N, Banov M, Adson D, Datto C, Raines S, et al. (2011). Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-c ontrolled, randomized study. J Affect Disord 128:83-94.
10. Boulenger JP, Hermes A, Huusom AK, Weiller E (2010). Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: Escitalo pram vs. paroxetine. Curr Med Res Opin 26:605-614.
11. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ (2000). Pittsburgh Sleep Quality Index (PSQI). In: Rush AJ, First MB, Blacker D, editors. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; pp. 678-680.
12. Byers AL, Yaffe K, Covinsky KE, Friedman MB, Bruce ML (2010). High occurrence of mood and anxiety disord ers among older adults: The National Comorbidity Survey Replication. Arch Gen Psychiatry 67:489-496.
13. Cohen J (1988). Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Earlbaum Associates.
14. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, A strom M, Brecher M (2009). Extended release quetiapine fumarate monotherapy in major depressive disorder: A placebo- and duloxetine-controlled study. J Clin Psychiatry 70:526-539.
15. DeVeaugh-Geiss AM, West SL, Miller WC, Sleath B, Gaynes BN, Kroenke K (2010). The adverse effects of comorbid pain on depression outcomes in primary care patients: Results from the ARTIST trial. Pain Med 11:732-741.
16. Dombrovski AY, Mulsant BH, Houck PR, Mazumdar S, Lenze EJ, Andreescu C, et al. (2007). Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affect Disord 103:77-82.
17. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, et al. (2010). Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadeq uate response to ongoing antidepressant treatment: A multicentre, randomized, doubleblind, placebo-controlled study. Int J Neuropsychopharmacol 13:917-932.
18. Folstein MF, Folstein SE, McHugh PR (1975). Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
19. Gallo JJ, Rabins PV (1999). Depression without sadness: Alternative presentations of depression in late life. Am Fam Physician 60:820-826.
20. Grau-Ló pez L, Sierra S, Mart́nez-Cáceres E, Ramo-Tello C (2011). Analysis of the pain in multiple sclerosis patients. Neurologia 26:208-213.
21. Guy W (1976). Clinical Global Impressions. In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education and Welfare; pp. 218-222.
22. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
23. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
24. Hawker GA, Mian S, Kendzerska T, French M (2011). Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SFMPQ ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 63 (Suppl 11):S240-S252.
25. Huang Y, Carpenter I (2011). Identifying elderly depression using the Depression Rating Scale as part of comprehensive standardised care assessment in nursing homes. Aging Ment Health 15:1045-1051.
26. Joyce CR, Zutshi DW, Hrubes V, Mason RM (1975). Comparison of fixed interval and visual analogue scales for rating chronic pain. Eur J Clin Pharmacol 8:415-420.
27. Kasper S, de Swart H, Friis Andersen H (2005). Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 13:884-891.
28. Katila H, Mezhebovsky I, Mulroy A, Berggren L, Eriksson H, Earley W, et al. (2013). Randomized, double-blind stud y of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry 21: 1769-1784.
29. Kessler RC, Gruber M, Hettema JM, Hwang I, Sampson N, Yonkers KA (2008). Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychol Med 38:365-374.
30. Kessler RC, Bir nbaum H, Bromet E, Hwang I, Sampson N, Shahly V (2010). Age differences in major depression: Results from the National Comorbidity Survey Replication (NCS-R). Psychol Med 40:225-237.
31. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H (2011). A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 31:418-428.
32. Kim JM, Stewart R, Kim SW, Yang SJ, Shin IS, Yoon JS (2009). Insomnia, depression, and physical disorders in late life: A 2-year longitudinal communi ty study in Koreans. Sleep 32:1221-1228.
33. Lenze EJ, Mulsant BH, Shear MK, Schulberg HC, Dew MA, Begley AE, et al. (2000). Comorbid anxiety disorders in depressed elderly patients. Am J Psychiatry 157:722-728.
34. Lieb R, Becker E, Altamura C (2005). The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 15:445-452.
35. Lin CH, Lane HY, Chen CC, Juo SH, Yen CF (2011). Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder. Clin J Pain 27:805-810.
36. Maierà E (2010). Old age depression and its treatment. Psychiatr Danub 22 (Suppl 1):S124-S125.
37. Mendlewicz J (2009). Sleep disturbances: Core symptoms of major depressive disorder rather than associated or comorbid disorders. World J Biol Psychiatry 10:269-275.
38. Merideth C, Cutler A, She F, Eriksson H (2012). Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of general ized anxiety disorder: A randomized, placebo-controlled and active-controlled study. Int Clin Psychopharmacol 27:40-54.
39. Mezhebovsky I, Magi K, She F, Datto C, Eriksson H (2013). Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry 28:615-625.
40. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
41. Montgomery SA, Moller HJ (2009). Is the significant superiority of escitalopram compared with other antidepressants clinically relevan t Int Clin Psychopharmacol 24:111-118.
42. Nelson JC, Delucchi K, Schneider LS (2008). Efficacy of second generation antidepressants in late-life depression: A meta-analysis of the evidence. Am J Geriatr Psychiatry 16:558-567.
43. Paul SM, Zelman DC, Smith N, Miaskowski C (2005). Categorizing the severity of cancer pain: Further exploration of the establishment of cutpoints. Pain 113:37-44.
44. Pigeon WR, Hegel M, Unutzer J, Fan MY, Sateia MJ, Lyness JM, et al. (2008). Is insomnia a perpetuating factor for late-life depression in the IMPACT cohort Sleep 31:481-488.
45. Pinson L, Gray GE (2003). Psychopharmacology: Number needed to treat: An underused measure of treatment effect. Psychiatr Serv 54:145 -146, 154.
46. Reynolds CF III, Dew MA, Martire LM, Miller MD, Cyranowski JM, Lenze E, et al. (2010). Treating depression to remission in older adults: A controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management. Int J Geriatr Psychiatry 25:1134-1141.
47. Schatzberg A, Roose S (2006). A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 14:361-370.
48. Schneider LS, Dagerman KS, Insel P (2005). Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 294:1934-1943.
49. Schneider E, Linden M, Weigmann H, Wagner T, Quail D, Hundemer HP, et al. (2011). Early reduction in painful physical symptoms is associated with improvements in long-term depression outcomes in pat ients treated with duloxetine. BMC Psychiatry 11:150.
50. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (M. I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20):22-33.
51. Sheikh JI, Cassidy EL, Doraiswamy PM, Salomon RM, Hornig M, Holland PJ, et al. (2004). Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. J Am Geriatr Soc 52: 86-92.
52. Sussman N (2003). SNRIs ve rsus SSRIs: Mechanisms of action in treating depression and painful physical symptoms. Prim Care Companion J Clin Psychiatry 5 (Suppl 7):19-26.
53. Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papa kostas GI (2011). Efficacy of antidepressants for late-life depression: A meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry 72:1660-1668.
54. Thase ME, Demyttenaere K, Ear ley W, Gustafsson U, Udd M, Eriksson H (2012). Extended release quetiapine fumarate in major depressive disorder: Analysis in patients with anxious depression. Depress Anxiety 29:574-586.
55. Tollefson GD, Bosomworth JC, Heiligenstein JH, Potvin JH, Holman S (1995). A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group. Int Psychogeriatr 7:89-104.
56. Trivedi MH, Bandelow B, Demyttenaere K, Papakosts GI, Szamosi J, Earley W, et al. (2013). Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: A pooled analysis of four randomized acute studies. Int J Neuropsychopharmacol 16:1733-1744.
57. Vaccarino AL, Sills TL, Evans KR, Kalali AH (2008). Prevalence an d association of somatic symptoms in patients with major depressive disorder. J Affect Disord 110:270-276.
58. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H (2009). Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized, placebo-controlled study. CNS Spectr 14:299-313.
59. Zimmerm an M, McDermut W, Mattia JI (2000). Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. Am J Psychiatry 157:1337-1340.